Johnson & Johnson
DUS:JNJ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Johnson & Johnson
DUS:JNJ
|
US |
|
M
|
Medibank Private Ltd
XMUN:MPV
|
AU |
Intrinsic Value
The intrinsic value of 
Johnson & Johnson (JNJ) under the Base Case is 157.95 EUR per share.
Compared with the current market price of 238.25 EUR, the stock appears
Overvalued by 34% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Johnson & Johnson Does
Johnson & Johnson is a healthcare company that sells prescription medicines and medical devices. Its drug business focuses on treatments in areas such as immunology, oncology, neuroscience, and infectious disease, while its medical technology business sells products used in surgery, orthopedics, vision care, and other hospital and clinic settings. It no longer includes the consumer health brands that were separated into Kenvue.
- Headquarters
- United States of America US
- Employees
- 138 200
- IPO date
- Sep 25, 1944
Johnson & Johnson has a wide economic moat
Patents and exclusive drug rights prevent rivals from copying important treatments, while hospitals’ investment in specialized equipment and staff training makes changing suppliers costly. Johnson & Johnson combines these protections across medicines and medical devices rather than depending on a single product.
Read the full moat analysis
Revenue & Expenses Breakdown
Johnson & Johnson
Earnings Waterfall
Johnson & Johnson
The intrinsic value for Johnson & Johnson (JNJ) under the Base Case is 157.95 EUR.
Compared with the current market price of 238.25 EUR, the stock appears Overvalued by 34% .